Retinopathy - Pipeline Review, H2 2012

Description: Retinopathy - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Retinopathy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinopathy.
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Retinopathy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Retinopathy 8
Retinopathy Therapeutics under Development by Companies 10
Retinopathy Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Retinopathy Therapeutics – Products under Development by Companies 18
Retinopathy Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Retinopathy Therapeutics Development 20
NsGene A/S 20
BioLineRx, Ltd. 21
Insmed Incorporated 22
Acucela Inc. 23
Gene Signal International SA. 24
Indus Biotech Private Limited 25
Affichem 26
SIFI Pharma 27
EyeGene, Inc. 28
Eleven Biotherapeutics 29
Retinopathy – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
mecasermin rinfabate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug For Retinopathy Of Prematurity - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BL-8010 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AF-243 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
INDUS-815C - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SF-113 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NsG-31 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
aganirsen - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
propranolol hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rituximab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bevacizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
mecasermin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
inositol niacinate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
interferon gamma-1b - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bevacizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
EG-Mirotin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
methotrexate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
betaxolol hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drug For Retinopathy/Neuropathy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Retinopathy Therapeutics – Drug Profile Updates 57
Retinopathy Therapeutics – Discontinued Products 59
Retinopathy Therapeutics - Dormant Products 60
Retinopathy – Product Development Milestones 61
Featured News & Press Releases 61
May 08, 2012: Gene Signal Presents Preclinical Data Of Aganirsen At ARVO Annual Meeting 61
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease 62
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Number of Products Under Development for Retinopathy, H2 2012 8
Products under Development for Retinopathy – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Retinopathy - Pipeline Review, H2 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2366364/">http://www.researchandmarkets.com/reports/2366364/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2ILFL</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>□</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>□</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>□</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World